Jan 12
2022
Phanes Therapeutics announces the appointment of Vice President of Business Development
SAN DIEGO, Jan. 11, 2022 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research in immuno-oncology announced today that...
Read More
Dec 16
2021
PHANES THERAPEUTICS TO PRESENT AT BIOTECH SHOWCASE™ 2022 IN SAN FRANCISCO – Company expects to file three INDs in 2022
SAN DIEGO, Dec. 15, 2021 /PRNewswire/ -- Phanes Therapeutics, Inc., an emerging biotech company focused on innovative drug discovery and development in...
Read More
Sep 13
2021
Phanes Therapeutics reveals SPECpair™ technology platform that enhances manufacturability of bispecific antibodies
SAN DIEGO, Sept. 10, 2021 Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative drug discovery research and development in immuno-oncology...
Read More
May 25
2021
Phanes Therapeutics Announces $40 million Series B Financing
SAN DIEGO and SHANGHAI, May 25, 2021 Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative drug discovery in immuno-oncology,...
Read More
Jun 16
2020
Phanes Therapeutics reveals a new bispecific antibody technology platform at BIO Digital 2020
SAN DIEGO, June 16, 2020 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research in immuno-oncology...
Read More
Dec 12
2019
PHANES THERAPEUTICS TO PRESENT AT BIOTECH SHOWCASE™ 2020 IN SAN FRANCISCO
San Diego, California/December 12, 2019 – Phanes Therapeutics, Inc., an emerging biotech company focused on innovative drug discovery in immuno-oncology,...
Read More
Nov 7
2019
PHANES AND FOSUN KITE FORM STRATEGIC ALLIANCE FOR INNOVATIVE CAR-T PRODUCTS TO TREAT SOLID TUMORS
Phanes Therapeutics and Phanes Biopharmaceuticals (“Phanes”) recently formed an important strategic alliance with Fosun Kite Biotechnology (“Fosun Kite”). Under the...
Read More
Sep 17
2019
PHANES AND HANMI ANNOUNCE LICENSING AGREEMENT TO DEVELOP BI- AND/OR MULTI-SPECIFIC ANTIBODIES
Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research in immuno-oncology announced today that it has signed a...
Read More
Jul 24
2019
MERCK TO PROVIDE BIORELIANCE® END-TO-END SOLUTIONS TO PHANES THERAPEUTICS
Collaboration to accelerate development and manufacturing of Bispecific Antibody Merck plans to offer Phanes a full suite of products and...
Read More
Mar 13
2018
CROWNBIO ENTERS STRATEGIC PARTNERSHIP WITH PHANES THERAPEUTICS TO ACCELERATE DISCOVERY AND DEVELOPMENT OF PHANES’ NOVEL ONCOLOGY AGENTS
Original link: https://blog.crownbio.com/press/partnership-with-phanes (San Diego, Calif., March 13, 2018) — Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:...
Read More
